Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (70)

61

Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia : a systematic review and meta-analysis

enthalten in: Hematology (Amsterdam, Netherlands) | 2017

von Wu, Y. | Wang, Y. | Gu, Y. | +4

62

Ramucirumab in the treatment of non-small cell lung cancer

enthalten in: Expert opinion on drug safety | 2017

von Arrieta, O. | Zatarain-Barrón, Z. | Cardona, A. | +2

ErratumIn: Expert Opin Drug Saf. 2017 May;16(5):645. - PMID 28471295

63

Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy : How Low Is Too Low?

enthalten in: Journal of the American College of Cardiology | 2017

von Everett, B.

CommentOn: J Am Coll Cardiol. 2017 Feb 7;69(5):471-482. - PMID 28153102

64

Sarilumab (Kevzara)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, May 2017

CADTH common drug review clinical review report

65

Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Erschienen: Ottawa (ON), CADTH, December 2017

CADTH common drug review clinical review report

66

Ixekizumab (Taltz)

Erschienen: Ottawa (ON), CADTH, September 2017

Common drug review clinical review report

67

Idarucizumab for reversing anticoagulation in adults treated with dabigatran : a review of the clinical effectiveness, cost-effectiveness, and guidelines

Erschienen: Ottawa, ON, Canadian Agency for Drugs and Technologies in Health, 31 January 2017

Rapid response report: peer-reviewed summary with critical appraisal

68

Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease : Need for Prognostic Biomarkers?

enthalten in: Journal of Alzheimer's disease : JAD | 2016

von Piazza, F. | Winblad, B.

69

Medication-related osteonecrosis of the jaws : bisphosphonates, denosumab, and new agents

Erschienen: Berlin, Springer, 2015

von Otto, S.

70

Tocilizumab (Actemra, intravenous) : for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs and systemic corticosteroids

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, [2014]

Common drug review

[1]
« Vorheriger
1
2
3
4
5
6
7